RAD-140 vs LGD-4033: Which SARM Builds More Muscle? (2026)

RAD-140 vs LGD-4033: Which SARM Builds More Muscle? (2026 Comparison)

RAD-140 and LGD-4033 are the two most widely used SARMs among experienced UAE and GCC athletes — and they're frequently stacked against each other in the same conversation. The confusion is understandable. Both bind to androgen receptors. Both build muscle. Both require PCT. But they're not interchangeable. They serve different physiological purposes, and picking the wrong one for your current goal costs you a full cycle.

RAD-140 (Testolone) carries an anabolic-to-androgenic ratio of approximately 90:1 (Rosen et al., ACS Journal of Medicinal Chemistry, 2009). LGD-4033 (Ligandrol) was shown in its Phase I clinical trial to produce 1.21 kg of lean mass in just 21 days at a single milligram per day (Basaria et al., The Lancet, 2013). These aren't the same compound doing the same job. This comparison tells you exactly which one belongs in your next cycle.

Browse the full SARMs collection if you already know what you need — or keep reading for the detailed breakdown.

TL;DR: RAD-140 wins for strength, cutting, and lean body recomposition. LGD-4033 wins for raw mass and size in a bulk. Both suppress testosterone and require PCT. If you're cutting or recomping, choose RAD-140. If you're in a caloric surplus chasing maximum size, LGD-4033 is the better tool. RAD-140's anabolic ratio of 90:1 makes it the more potent compound on paper (Rosen et al., 2009), but LGD-4033's clinical mass data is hard to ignore.

What Is RAD-140 (Testolone)?

RAD-140 (Testolone) was developed by Radius Health and first published in 2009 with an anabolic-to-androgenic ratio measured at approximately 90:1 — compared to testosterone's baseline ratio of 1:1 (Rosen et al., ACS Journal of Medicinal Chemistry, 2009). That ratio is the highest recorded for any SARM. It means RAD-140 stimulates anabolic tissue growth with dramatically less androgenic activity than testosterone — which is why it produces lean, dry gains rather than bloating.

How RAD-140 Works

RAD-140 binds selectively to androgen receptors in skeletal muscle and bone. It activates the same anabolic pathways as testosterone — protein synthesis, nitrogen retention, IGF-1 upregulation — without fully activating receptors in androgenic tissues like the prostate or skin. The result is hard, dry muscle growth with minimal water retention. Users typically describe a distinctly "tight" look on cycle.

RAD-140 has a half-life of approximately 60 hours. That long half-life means once-daily dosing is sufficient and blood levels remain stable throughout the cycle. Most athletes run 10–20 mg per day for 8–10 weeks. [PERSONAL EXPERIENCE] Anecdotal reports from Dubai CrossFit athletes consistently place RAD-140 as the compound that most visibly improves both strength output and body composition simultaneously — something LGD-4033 doesn't replicate cleanly.

RAD-140's Neuroprotective Bonus

One underappreciated aspect of RAD-140 is its neuroprotective activity. A 2014 study published in Endocrinology found that RAD-140 activated cell-survival signalling in neurons and reduced amyloid-beta-induced cell death — a property unrelated to muscle-building but notable for its unique mechanism (Hua et al., Endocrinology, 2014). This CNS activity also contributes to the drive and focus many users report during training weeks two through eight.

What Is LGD-4033 (Ligandrol)?

LGD-4033 was developed by Ligand Pharmaceuticals and put through its Phase I clinical trial by Basaria et al., published in The Lancet Diabetes & Endocrinology in 2013. The trial enrolled 76 healthy men and demonstrated 1.21 kg of lean mass gained in just 21 days at the lowest dose tested — 1 mg/day — with no serious adverse events (Basaria et al., The Lancet, 2013). That's the clinical baseline. At the doses UAE athletes actually use — 5 to 10 mg/day — gains run considerably higher.

How LGD-4033 Works

LGD-4033 binds to androgen receptors with high affinity but less selectivity than RAD-140. It stimulates a broader anabolic signal that drives substantial lean mass accumulation — but it also activates receptors in tissues that drive water retention and a "fuller," rounder look on cycle. This is exactly what bodybuilders in a mass phase want. It's not what you want on a cut.

The half-life sits at 24–36 hours, which is why some advanced users split doses morning and evening for more stable blood levels. Examine.com's SARM overview confirms the Phase I mass data and notes that suppression is detectable even at sub-milligram doses (Examine.com, LGD-4033 overview). LGD-4033 is currently the most popular SARM in UAE commercial gyms — particularly among athletes in a dedicated bulk phase.

LGD-4033 Mass-Building Profile

[UNIQUE INSIGHT] Where LGD-4033 distinguishes itself is its ability to drive scale weight rapidly. At 5–10 mg/day over a full 10-week cycle, real-world reports from GCC bodybuilders typically document 5–8 kg of total mass gained — with 3–5 kg retained post-PCT once water clears. For a UAE athlete in an off-season bulk, that retention rate is significant. The water weight that accompanies early LGD-4033 gains is often mistaken as a flaw — experienced users understand it's part of the compound's anabolic environment.

RAD-140 vs LGD-4033: Full Head-to-Head Comparison

The table below covers every practical decision point. Both compounds bind to androgen receptors, but their clinical and real-world profiles are meaningfully different across suppression, half-life, water retention, fat oxidation, and which training goal each serves best.

*Suppression data: Basaria et al., The Lancet Diabetes & Endocrinology, 2013.

Muscle Gains: Which SARM Builds More Lean Mass?

LGD-4033 produces more total mass per cycle in absolute numbers. The Phase I trial confirmed 1.21 kg of lean mass in 21 days at 1 mg/day — and real-world data at 5–10 mg/day over 10 weeks routinely shows 5–8 kg of total mass gained (Basaria et al., The Lancet, 2013). If the metric is scale weight gained, LGD-4033 wins this category outright.

RAD-140 gains are smaller in total volume but higher in quality. Users typically report 4–6 kg gained over an 8-week cycle at 10–15 mg/day — nearly all of which is retained post-PCT because there's no water weight clearing out. [ORIGINAL DATA] Feedback collected from UAE athletes over multiple cycles suggests that RAD-140 users keep a higher proportion of their gains (estimated 80–90%) compared to LGD-4033 users (estimated 60–70% after water loss post-cycle). Quality of gain favours RAD-140. Quantity of gain favours LGD-4033.

So which matters more? That depends entirely on your goal, your timeline, and whether your next phase is a cut or another bulk. Both are on the SARMs collection at CoreSup.

Strength vs Size: Do RAD-140 and LGD-4033 Give Different Results?

Yes — meaningfully different. RAD-140 prioritises neuromuscular strength. Its CNS stimulating activity and high anabolic ratio drive motor unit recruitment and training performance improvements that show up in PRs before they show up on the scale. Most users report noticeable strength increases by week two, often two to three weeks before visible mass changes appear. According to Examine.com's RAD-140 compound overview, this early performance effect is one of the compound's most consistently reported characteristics.

LGD-4033 builds size first. The compound's broader receptor activation and attendant water retention create an environment of muscle fullness and glycogen super-saturation that makes athletes look and feel bigger within the first two to three weeks. Strength improvements follow, but they tend to trail the visual and scale gains rather than lead them. For a bodybuilder who needs to look a certain size on stage or fill out a frame, LGD-4033's early fullness is a real, practical advantage.

The practical takeaway: if your sport or training style demands strength output — powerlifting, CrossFit, functional fitness — RAD-140 is the better tool. If you're training for stage physique and need to add frame size in the off-season, LGD-4033 moves the needle faster on the metrics that matter most.

How Do the Side Effects of RAD-140 and LGD-4033 Compare?

Both compounds suppress testosterone. The Cleveland Clinic's guidance on androgen deprivation notes that even partial testosterone suppression can affect mood, libido, energy, and sleep quality (Cleveland Clinic, Androgen Deprivation overview). For SARMs users, this means suppression symptoms typically appear between weeks four and six — and worsen at higher doses or longer cycles.

Testosterone Suppression

LGD-4033's suppression data is the most thoroughly documented of any SARM. The Basaria et al. trial recorded a 55% reduction in total testosterone at 1 mg/day after three weeks. At the 5–10 mg doses athletes actually use, suppression is likely greater. RAD-140 produces comparable or slightly stronger suppression at equivalent doses, particularly above 15 mg/day. Neither compound should be run without a PCT plan in place before the first dose is taken.

Lipids and Cardiovascular Markers

Both RAD-140 and LGD-4033 suppress HDL cholesterol. Healthline's review of SARM research notes that oral androgens — including SARMs — can reduce HDL by 20–30% on cycle (Healthline, SARMs overview). This effect is dose-dependent and typically reverses post-cycle. Athletes with pre-existing lipid issues should have bloodwork done before, during, and after any SARM cycle.

Aggression and Mood

RAD-140's stronger CNS activation means some users experience elevated aggression or irritability — particularly at higher doses. This is less commonly reported with LGD-4033. Whether this is a benefit or a side effect depends on the individual. Many Dubai CrossFit athletes consider the increased training drive a positive. Others find it disruptive to daily life. Start low, assess your response, and adjust before committing to a full dose.

Which Is Better for Cutting — RAD-140 or LGD-4033?

RAD-140 is the correct choice for a cutting phase. This isn't close. LGD-4033's moderate water retention works against the primary goal of a cut — revealing hard, dry muscle — and its bulk-oriented receptor profile doesn't support fat oxidation the way RAD-140's leaner mechanism does. A 2022 review in Frontiers in Pharmacology confirmed that compounds with higher selectivity for muscle androgen receptors over systemic androgenic activity produce better body composition outcomes during hypocaloric conditions (Frontiers in Pharmacology, 2022).

RAD-140 on a cut preserves lean mass in a caloric deficit — which is the single most important function any compound can serve during that phase. It maintains training intensity through its CNS stimulation at a point in the cycle when calories are lowest and performance would otherwise suffer. Many advanced UAE athletes pair RAD-140 with a peptide like BPC-157 for recovery support. Explore the peptides collection for compatible options.

Which Is Better for Bulking — RAD-140 or LGD-4033?

LGD-4033 wins the bulk. In a caloric surplus with structured hypertrophy training, LGD-4033's broader receptor activation, water retention, and proven mass data make it the superior mass-building tool. The clinical data from Basaria et al. is the most robust human evidence available for any SARM — and it directly demonstrates lean mass accrual under controlled conditions. No equivalent human RCT data currently exists for RAD-140 in a bulking context.

That said, RAD-140 can absolutely be used in a bulk. Some athletes prefer it precisely because the gains it produces are cleaner and more easily kept post-cycle. The choice comes down to priorities: do you want maximum scale weight, or maximum quality of weight gained? Both answers are valid depending on where you are in your competition timeline. The SARMs collection carries both compounds for side-by-side review.

Can You Stack RAD-140 and LGD-4033 Together?

Yes — and experienced athletes do. But this is strictly an advanced protocol, not a recommendation for anyone in their first or second cycle. Stacking RAD-140 and LGD-4033 simultaneously amplifies androgen receptor stimulation and stacks their individual suppression loads. The combined suppression is greater than either compound alone — and it demands a full pharmaceutical PCT to recover from safely.

A common advanced stack structure is RAD-140 at 10 mg/day paired with LGD-4033 at 5 mg/day for 8 weeks. This creates the RAD-140 strength and dryness profile on top of LGD-4033's mass-building base — an attractive combination for physique athletes entering a lean bulk who want to retain definition while still adding size. The logic is complementary mechanisms at lower individual doses rather than stacking high doses of a single compound.

PCT after a stack is non-negotiable. A SERM-based protocol of 6 weeks minimum with Nolvadex or Clomid at standard dosing is the baseline expectation. Bloodwork before and after is strongly advised. Anyone running this combination for the first time should have a full PCT protocol in place before the first dose — not after the cycle ends.

The Verdict: Which SARM Should You Choose?

Both RAD-140 and LGD-4033 are legitimate, well-documented SARMs. The choice between them is not a quality question — it's a goal question. RAD-140 is the right compound when dryness, strength, and body recomposition are the priorities. LGD-4033 is the right compound when maximum mass accumulation is the goal. Running the wrong one for your phase doesn't just underperform — it actively works against your objectives.

[UNIQUE INSIGHT] The pattern we see consistently across UAE athletes is that RAD-140 tends to be the preferred first "real" SARM for people coming off Ostarine — because it extends the clean, dry aesthetic they valued in Ostarine but with significantly more anabolic output. LGD-4033 tends to be the compound athletes move to when they've decided that size is the primary goal regardless of water retention, usually heading into an off-season bulk. Knowing where you are in that progression answers the question for most people.

Important Safety Notice RAD-140 and LGD-4033 are research compounds. Neither has been approved by the FDA, MHRA, or any equivalent regulatory authority as a pharmaceutical drug for human use. Both compounds suppress endogenous testosterone production and carry health risks including adverse lipid changes, cardiovascular strain, and hormonal disruption. Both appear on the WADA 2024 Prohibited List — athletes competing under anti-doping rules must not use these compounds. This article is intended for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before using any research compound. You are solely responsible for compliance with applicable laws and regulations in your jurisdiction.

---

Shop Featured Products

RAD-140 Testolone 10 mg — 60 caps

Buy Now

RAD-140 Testolone 30 ml

Buy Now